York Instruments, Ltd, a subsidiary of Croton Healthcare, LLC, has completed the acquisition of Stockholm, Sweden-based Elekta’s magnetoencephalography (MEG) business. MEG is a diagnostic functional neuroimaging technique for mapping brain activity and spotting abnormalities.
Elekta’s MEG business, known as MEGIN, is a leading supplier of magnetoencephalography (MEG) technology, with more than 100 delivered MEG systems worldwide. In FY2017-2018, MEGIN net sales of approximately $11 million. MEG is the primary business focus of U.K.-based York Instruments, which has a U.S. office in Coral Springs, Fla.
Elekta has been looking to divest MEGIN due to a recent “strategic decision that it is no longer a part of our core treatment solutions and oncology informatics business,” says Maurits Wolleswinkel, head of portfolio and chief strategy officer for Elekta, which he adds will continue to be engaged in sales and support during the transition of business ownership.
“The combination of Elekta’s experience and York Instruments’ advanced technology provides an exciting new future for MEG. We look forward to serving Elekta’s current customers and expanding the MEG market beyond its current borders,” says Gordon Baltzer, CEO of York Instruments.
